JP2024534517A - Erbb阻害剤としての多形 - Google Patents

Erbb阻害剤としての多形 Download PDF

Info

Publication number
JP2024534517A
JP2024534517A JP2024517482A JP2024517482A JP2024534517A JP 2024534517 A JP2024534517 A JP 2024534517A JP 2024517482 A JP2024517482 A JP 2024517482A JP 2024517482 A JP2024517482 A JP 2024517482A JP 2024534517 A JP2024534517 A JP 2024534517A
Authority
JP
Japan
Prior art keywords
degrees
compound
radiation
cancer
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024517482A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534517A5 (cg-RX-API-DMAC10.html
Inventor
チャン ウー-イェン
フォルーギ レーザ
スーイー チアン
メイチー リー
チュアンチュアン シー
Original Assignee
ブラック ダイアモンド セラピューティクス,インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブラック ダイアモンド セラピューティクス,インコーポレイティド filed Critical ブラック ダイアモンド セラピューティクス,インコーポレイティド
Publication of JP2024534517A publication Critical patent/JP2024534517A/ja
Publication of JP2024534517A5 publication Critical patent/JP2024534517A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024517482A 2021-09-21 2022-09-21 Erbb阻害剤としての多形 Pending JP2024534517A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163246451P 2021-09-21 2021-09-21
US63/246,451 2021-09-21
PCT/US2022/044232 WO2023049168A1 (en) 2021-09-21 2022-09-21 Polymorphs as erbb inhibitors

Publications (2)

Publication Number Publication Date
JP2024534517A true JP2024534517A (ja) 2024-09-20
JP2024534517A5 JP2024534517A5 (cg-RX-API-DMAC10.html) 2025-09-30

Family

ID=83691602

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024517482A Pending JP2024534517A (ja) 2021-09-21 2022-09-21 Erbb阻害剤としての多形

Country Status (10)

Country Link
US (1) US20240425492A1 (cg-RX-API-DMAC10.html)
EP (1) EP4405350A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024534517A (cg-RX-API-DMAC10.html)
KR (1) KR20240099193A9 (cg-RX-API-DMAC10.html)
CN (1) CN119110799A (cg-RX-API-DMAC10.html)
AU (1) AU2022352658A1 (cg-RX-API-DMAC10.html)
CA (1) CA3231697A1 (cg-RX-API-DMAC10.html)
IL (1) IL311354A (cg-RX-API-DMAC10.html)
MX (1) MX2024003475A (cg-RX-API-DMAC10.html)
WO (1) WO2023049168A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020328598B2 (en) 2019-08-15 2026-07-02 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
WO2024179451A1 (zh) * 2023-03-02 2024-09-06 江苏康缘药业股份有限公司 一种炔基取代的喹唑啉化合物的晶型、其制备方法和应用
WO2025038731A1 (en) * 2023-08-15 2025-02-20 Black Diamond Therapeutics, Inc. Method of treating cancers with alkyne substituted quinazoline derivatives
CN122580302A (zh) * 2023-12-21 2026-08-14 黑钻治疗公司 Erbb抑制剂的固体形式
WO2025137421A1 (en) * 2023-12-21 2025-06-26 Black Diamond Therapeutics, Inc. Compositions comprising alkyne substituted quinazoline derivatives and related uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021030711A1 (en) * 2019-08-15 2021-02-18 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023004998A (es) * 2020-11-02 2023-05-12 Black Diamond Therapeutics Inc Metodo para tratar canceres con derivados de quinazolina sustituida con alquino.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021030711A1 (en) * 2019-08-15 2021-02-18 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
平山令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0005875707 *
芦澤 一英: "塩・結晶形の最適化と結晶化技術", PHARM TECH JAPAN, vol. 18, no. 10, JPN6013060608, 2002, pages 81 - 96, ISSN: 0005875709 *
芦澤一英, 医薬品の多形現象と晶析の科学, JPN6018028449, 2002, pages 56 - 102, ISSN: 0005875710 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, JPN6009053755, 15 January 2007 (2007-01-15), ISSN: 0005875708 *

Also Published As

Publication number Publication date
IL311354A (en) 2024-05-01
EP4405350A1 (en) 2024-07-31
KR20240099193A9 (ko) 2025-12-10
MX2024003475A (es) 2024-04-05
KR20240099193A (ko) 2024-06-28
CN119110799A (zh) 2024-12-10
CA3231697A1 (en) 2023-03-30
AU2022352658A1 (en) 2024-03-21
US20240425492A1 (en) 2024-12-26
WO2023049168A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
US20240425492A1 (en) Polymorphs as erbb inhibitors
US20220194946A1 (en) Fgfr inhibitors and methods of making and using the same
US20140309192A1 (en) Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto
JP6657294B2 (ja) ニューロトロフィン模倣化合物およびこれらの塩の結晶形態
EP3394070B1 (en) Crystalline forms of quinolone analogs and their salts
US12215083B2 (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
US9957282B2 (en) Crystalline forms of quinolone analogs and their salts
US20220162177A1 (en) Crystalline forms of neurotrophin mimetic compounds and their salts
KR20090122218A (ko) 5-(2,4-디히드록시-5-이소프로필-페닐)-4-(4-모르폴린-4-일메틸-페닐)-이속사졸-3-카르복실산 에틸아미드의 산 부가염, 수화물 및 다형체, 및 이들 형태를 포함하는 제제
WO2015113521A1 (zh) 氘代喹唑啉酮化合物以及包含该化合物的药物组合物
EP3390369A1 (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
WO2025137424A1 (en) Solid forms of an erbb inhibitor
WO2025226822A2 (en) Forms and salts of 6-aza-quinoline derivatives and related uses
WO2025117550A1 (en) Solid state forms of a quinoxaline derivative useful in the treatment of cancer
JP2018525393A (ja) 化合物n−(3,5−ジメチルフェニル)−n’−(2−トリフルオロメチルフェニル)グアニジンの調製方法
HK1234747B (en) Salts and polymorphs of a substituted imidazopyridinyl-aminopyridine compound

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260602